Report this content

The shareholders in Attana AB, org. no. 556931–4106 (the “Company”), are hereby invited to the Extraordinary General Meeting on Monday, November 9, 2020 at 10.00 at the Company's office, Greta Arwidssons Väg 21, 114 19 Stockholm.


Shareholders who wish to participate in the Extraordinary General Meeting shall:

(i) be recorded in the share register kept by Euroclear Sweden AB on Friday, on October 30, 2020, and

(ii) notify its intention to participate in the Extraordinary General Meeting to the Company no later than Monday, November 2, 2020.

Registration is made to the Company's e-mail: or in writing to the Company's address; Attana AB, Greta Arwidssons Väg 21, 114 19 Stockholm. Upon registering, the name, personal or organization number, address, telephone number and number of any attendees or accompanying advisors, if any, must be stated.


Shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their own names in the share register maintained by Euroclear Sweden AB in order to be entitled to attend and vote at the Extraordinary General Meeting. Such registration must be completed with Euroclear Sweden AB no later than Tuesday, November 3, 2020 and must therefore be requested from the nominee well in advance of this date.


Shareholders represented by proxy must submit a written, signed and dated power of attorney. If the power of attorney is issued by a legal entity, a certification of registration or an equivalent authorization document must be attached. The original version of the power of attorney and the certificate of registration, if applicable, shall be sent to the Company to the abovementioned address well in advance of the Extraordinary General Meeting. A template proxy form is available on the Company’s website,


1. Opening of the meeting.
2. Election of chairman of the meeting.
3. Preparation and approval of the voting list.
4. Election of one or two persons to verify the minutes.
5. Determination of whether the meeting has been duly convened.
6. Approval of the agenda.
7. Presentation of documents in accordance with the Swedish Companies Act (sw. Aktiebolagslagen (2005:551) Section 13 Clause 6. 
8. Resolution on preferential right issue.
9. Resolution on authorizing the board of directors to decide on an overallotment share issue. 
10. Closing of the meeting.


Item 8 - Resolution on preferential right issue

The board of directors proposes that the Extra General Meeting resolves to increase the Company's share capital by a maximum of SEK 292,323.40 by, subject to the shareholders' preferential rights, an share issue of a maximum of 48,705,400 shares (the “Preferential Rights Issue”).

The share issue shall be addressed to existing shareholders, pro rata their shareholding on the record date, who, with the support of their preferential rights, shall have the right to subscribe for shares. Each share in the Company entitles to one (1) subscription right and seven (7) subscription rights entitle to subscription for two (2) new shares.

The subscription price amounts to SEK 1.30 per share. The new shares will be subscribed for during the period 3 – 17 December 2020. The record date is 2 December 2020.

The Preferential Rights Issue is conditional on the Company receiving approval from the Swedish Financial Supervisory Authority (sw. Finansinspektionen) of a prospectus for the Preferential Right Issue.

Item 9 - Resolution on authorizing the board of directors to decide on an overallotment share issue

The board of directors also proposes that the Extraordinary General Meeting resolves to authorize the board of directors to, within six (6) months of the decision on the Preferential Rights Issue, on one occasion, and with deviation from the shareholders' preferential rights, decide on an overallotment of shares to the subscribers in the Preferential Rights Issue who did not receive full allocation therein. The board of directors shall then have the right to decide that the shares issued in the overallotment share issue shall be paid for in the form of cash payment or by setting-off claims against the Company. The issue price and other issue terms shall (in addition to the above) correspond to the terms of the Preferential Rights Issue. The board of directors’ decision on the overallotment share issue may in total comprise a maximum increase of the Company's share capital of SEK 60,000 and a maximum of 10,000,000 shares.

The purpose of the authorization of an overallotment share issue and the reasons for deviating from the shareholders' preferential rights is to satisfy a possible oversubscription in the Preferential Rights Issue and thereby provide the Company with additional capital.


A resolution in accordance with the board of directors’ proposal under item 9 above requires that the resolution is decided by shareholders representing at least two thirds (2/3) of both the votes cast and the shares represented at the Extra General Meeting.


The complete proposal under item 8, a copy of the Company's annual report, the auditor's report and the board of directors report on significant events of the Company's financial position and the auditor's opinion on it will be available to the shareholders of the Company at the above address and on the Company's website no later than 2 weeks before the Extra General Meeting. The documents are also sent free of charge to the shareholders who request it from the Company and state their address.


Stockholm October 2020

Attana AB

The board of directors

For more information, please contact:

Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00

This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit or contact


Documents & Links